ONL Therapeutics

Executive Summary

ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies that protect and regenerate retinal cells in patients with serious ocular diseases such as glaucoma and retinal detachment. The company's innovative approach targets the Fas signaling pathway to inhibit apoptosis and promote neuroprotection in the eye, addressing the underlying cell death that leads to vision loss. Founded in 2009 and headquartered in Ann Arbor, Michigan, ONL Therapeutics has advanced its lead candidate into clinical trials, leveraging its expertise in both small molecules and RNA/gene therapy modalities. The company's platform holds promise for treating a range of retinal disorders with significant unmet medical need, and its progress through the clinic is closely watched by investors and ophthalmology specialists alike. As a private company with no public ticker, ONL Therapeutics relies on funding from investors and grants to support its research and development efforts. With a focus on preserving and restoring vision, the company is positioned in the competitive landscape of ocular therapeutics, where successful clinical outcomes could unlock substantial value.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead candidate in glaucoma50% success
• Q2 2026Series C financing or strategic partnership announcement70% success
• Q3 2026FDA IND clearance for second indication (retinal detachment)80% success